Administration, Intravesical: The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.Urinary Bladder: A musculomembranous sac along the URINARY TRACT. URINE flows from the KIDNEYS into the bladder via the ureters (URETER), and is held there until URINATION.BCG Vaccine: An active immunizing agent and a viable avirulent attenuated strain of Mycobacterium tuberculosis, var. bovis, which confers immunity to mycobacterial infections. It is used also in immunotherapy of neoplasms due to its stimulation of antibodies and non-specific immunity.Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.Cystitis: Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.Cystoscopy: Endoscopic examination, therapy or surgery of the urinary bladder.Urinary Bladder Diseases: Pathological processes of the URINARY BLADDER.Cystitis, Interstitial: A condition with recurring discomfort or pain in the URINARY BLADDER and the surrounding pelvic region without an identifiable disease. Severity of pain in interstitial cystitis varies greatly and often is accompanied by increased urination frequency and urgency.Urination: Discharge of URINE, liquid waste processed by the KIDNEY, from the body.Administration, Oral: The giving of drugs, chemicals, or other substances by mouth.Propantheline: A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.Urinary Bladder, Neurogenic: Dysfunction of the URINARY BLADDER due to disease of the central or peripheral nervous system pathways involved in the control of URINATION. This is often associated with SPINAL CORD DISEASES, but may also be caused by BRAIN DISEASES or PERIPHERAL NERVE DISEASES.Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.Urodynamics: The mechanical laws of fluid dynamics as they apply to urine transport.Mandelic Acids: Analogs or derivatives of mandelic acid (alpha-hydroxybenzeneacetic acid).Ureter: One of a pair of thick-walled tubes that transports urine from the KIDNEY PELVIS to the URINARY BLADDER.Urinary Bladder, Overactive: Symptom of overactive detrusor muscle of the URINARY BLADDER that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. URINARY INCONTINENCE may or may not be present.Cystotomy: Surgical incision or puncture into a URINARY BLADDER. Cystotomy may be used to remove URINARY CALCULI, or to perform tissue repair and reconstruction.Urothelium: The epithelial lining of the URINARY TRACT.Cystectomy: Used for excision of the urinary bladder.Mycobacterium bovis: The bovine variety of the tubercle bacillus. It is called also Mycobacterium tuberculosis var. bovis.Tuberculosis, Cardiovascular: Pathological conditions of the CARDIOVASCULAR SYSTEM caused by infection of MYCOBACTERIUM TUBERCULOSIS. Tuberculosis involvement may include the HEART; the BLOOD VESSELS; or the PERICARDIUM.Urinary Bladder Neck Obstruction: Blocked urine flow through the bladder neck, the narrow internal urethral opening at the base of the URINARY BLADDER. Narrowing or strictures of the URETHRA can be congenital or acquired. It is often observed in males with enlarged PROSTATE glands.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Dose-Response Relationship, Drug: The relationship between the dose of an administered drug and the response of the organism to the drug.Drug Administration Schedule: Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.Rats, Sprague-Dawley: A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.Ureteral Neoplasms: Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom.Immunotherapy: Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.Antibiotics, Antineoplastic: Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.Tuberculosis, Male Genital: MYCOBACTERIUM infections of the male reproductive tract (GENITALIA, MALE).Reflex, Abnormal: An abnormal response to a stimulus applied to the sensory components of the nervous system. This may take the form of increased, decreased, or absent reflexes.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Carcinoma in Situ: A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Urethra: A tube that transports URINE from the URINARY BLADDER to the outside of the body in both the sexes. It also has a reproductive function in the male by providing a passage for SPERM.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Urologic Surgical Procedures: Surgery performed on the urinary tract or its parts in the male or female. For surgery of the male genitalia, UROLOGIC SURGICAL PROCEDURES, MALE is available.Adjuvants, Immunologic: Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.Prostatism: Lower urinary tract symptom, such as slow urinary stream, associated with PROSTATIC HYPERPLASIA in older men.Injections, Intravenous: Injections made into a vein for therapeutic or experimental purposes.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.United States Food and Drug Administration: An agency of the PUBLIC HEALTH SERVICE concerned with the overall planning, promoting, and administering of programs pertaining to maintaining standards of quality of foods, drugs, therapeutic devices, etc.Urination Disorders: Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.Reflex: An involuntary movement or exercise of function in a part, excited in response to a stimulus applied to the periphery and transmitted to the brain or spinal cord.Rats, Wistar: A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain.Neuromuscular Agents: Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (NEUROMUSCULAR BLOCKING AGENTS), and drugs that act centrally as skeletal muscle relaxants (MUSCLE RELAXANTS, CENTRAL). Drugs used in the treatment of movement disorders are ANTI-DYSKINESIA AGENTS.Drug Administration Routes: The various ways of administering a drug or other chemical to a site in a patient or animal from where the chemical is absorbed into the blood and delivered to the target tissue.Hyperthermia, Induced: Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs.Botulinum Toxins, Type A: A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25.Mice, Inbred C57BLPentosan Sulfuric Polyester: A sulfated pentosyl polysaccharide with heparin-like properties.Hypogastric Plexus: A complex network of nerve fibers in the pelvic region. The hypogastric plexus distributes sympathetic fibers from the lumbar paravertebral ganglia and the aortic plexus, parasympathetic fibers from the pelvic nerve, and visceral afferents. The bilateral pelvic plexus is in its lateral extent.AcroleinUrinary Catheterization: Passage of a CATHETER into the URINARY BLADDER or kidney.Urologic Neoplasms: Tumors or cancer of the URINARY TRACT in either the male or the female.Aneurysm, Infected: Aneurysm due to growth of microorganisms in the arterial wall, or infection arising within preexisting arteriosclerotic aneurysms.Dogs: The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065)Antimetabolites, Antineoplastic: Antimetabolites that are useful in cancer chemotherapy.Parasympatholytics: Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS.Urine: Liquid by-product of excretion produced in the kidneys, temporarily stored in the bladder until discharge through the URETHRA.Administration, Intranasal: Delivery of medications through the nasal mucosa.Capsaicin: An alkylamide found in CAPSICUM that acts at TRPV CATION CHANNELS.Mitomycins: A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.Neurons, Efferent: Neurons which send impulses peripherally to activate muscles or secretory cells.Pressure: A type of stress exerted uniformly in all directions. Its measure is the force exerted per unit area. (McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)DeoxycytidineUrinary Bladder Calculi: Stones in the URINARY BLADDER; also known as vesical calculi, bladder stones, or cystoliths.Neurons, Afferent: Neurons which conduct NERVE IMPULSES to the CENTRAL NERVOUS SYSTEM.Mucous Membrane: An EPITHELIUM with MUCUS-secreting cells, such as GOBLET CELLS. It forms the lining of many body cavities, such as the DIGESTIVE TRACT, the RESPIRATORY TRACT, and the reproductive tract. Mucosa, rich in blood and lymph vessels, comprises an inner epithelium, a middle layer (lamina propria) of loose CONNECTIVE TISSUE, and an outer layer (muscularis mucosae) of SMOOTH MUSCLE CELLS that separates the mucosa from submucosa.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Urinary Tract: The duct which coveys URINE from the pelvis of the KIDNEY through the URETERS, BLADDER, and URETHRA.Injections, Intraperitoneal: Forceful administration into the peritoneal cavity of liquid medication, nutrient, or other fluid through a hollow needle piercing the abdominal wall.Vesico-Ureteral Reflux: Retrograde flow of urine from the URINARY BLADDER into the URETER. This is often due to incompetence of the vesicoureteral valve leading to ascending bacterial infection into the KIDNEY.Mice, Inbred C3HMuscle Contraction: A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.Kidney Pelvis: The flattened, funnel-shaped expansion connecting the URETER to the KIDNEY CALICES.Pelvis: The space or compartment surrounded by the pelvic girdle (bony pelvis). It is subdivided into the greater pelvis and LESSER PELVIS. The pelvic girdle is formed by the PELVIC BONES and SACRUM.Rats, Inbred F344Muscarinic Antagonists: Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.
(1/242) The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients.

We investigated the potential existence of differences in the distribution of T-lymphocyte subsets and in the proliferative response of these CD2+ cells to polyclonal mitogens in patients with transitional cell bladder carcinoma (SBTCC) treated with prophylactic intracavitary instillations of bacillus Calmette-Guerin (BCG) according to their clinical response to this treatment. Before BCG treatment, different subset distribution (CD8+ and CD3+ CD56+), activation antigen expression (CD3+ HLA- DR+) and proliferative response to mitogenic signals were found in CD2+ cells from SBTCC patients prophylactically treated with BCG who remained free of disease or those who had recurrence of tumour. Otherwise, the prophylactic intracavitary BCG instillations in SBTCC patients are associated with a transitory variation of T-lymphocyte subset distribution (CD4 and CD8) and activation antigens expression (CD25).  (+info)

(2/242) Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy.

We report a case of Mycobacterium bovis BCG vertebral osteomyelitis in a 79-year-old man 2.5 years after intravesical BCG therapy for bladder cancer. The recovered isolate resembled M. tuberculosis biochemically, but resistance to pyrazinamide (PZA) rendered that diagnosis suspect. High-pressure liquid chromatographic studies confirmed the diagnosis of M. bovis BCG infection. The patient was originally started on a four-drug antituberculous regimen of isoniazid, rifampin, ethambutol, and PZA. When susceptibility studies were reported, the regimen was changed to isoniazid and rifampin for 12 months. Subsequently, the patient was transferred to a skilled nursing facility for 3 months, where he underwent intensive physical therapy. Although extravesical adverse reactions are rare, clinicians and clinical microbiologists need to be aware of the possibility of disseminated infection by M. bovis BCG in the appropriate setting of clinical history, physical examination, and laboratory investigation.  (+info)

(3/242) Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs.

More active and well-tolerated agents are needed for the treatment of superficial bladder cancer. This study investigated intravesical gemcitabine to establish the toxicology and pharmacokinetics necessary for clinical trials. Beagle dogs (in groups of 2; n = 6) received 100 mg, 350 mg, or 1 g of drug by intravesical administration on alternate days three times/week for 4 weeks. Animals were observed for clinical signs of toxicity; gemcitabine levels and peripheral blood counts were taken three times weekly. The dogs were euthanized, and a full necropsy was performed at days 1 and 14 after the last dose. Intravesical gemcitabine was given at 100 mg (n = 2), 350 mg (equivalent to the 1000 mg/m2 human dose; n = 3), and 3.5 g (n = 1). i.v. gemcitabine was given at 350 mg (n = 2). Plasma samples drawn at time points up to 8 h were analyzed for systemic absorption and clearance of drug. Doses of 100 and 350 mg were well tolerated with no clinical side effects. Necropsies revealed normal bone marrow cellularity and normal bladder histology. At 1 g, signs of severe clinical toxicity were evident, and after only three doses, necropsies demonstrated severe bone marrow hypoplasia, cystitis, and intestinal necrosis. At all intravesical doses, significant systemic absorption was seen. The T1/2 (+/- SD) for intravesical and i.v. administration of 350 mg was 328 (+/-6.8) min and 99.3 (+/-5.2) min, respectively (P<0.001). Intravesical gemcitabine is well tolerated and has no direct bladder toxicity at doses up to 1000 mg/m2. Higher doses result in gastrointestinal, bladder, and bone marrow toxicity.  (+info)

(4/242) Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin.

Although Mycobacterium bovis bacillus Calmette-Guerin (BCG) has been accepted as the most effective agent in clinical use against superficial bladder cancer, its mechanism of action remains incompletely understood. A kinetic analysis in assessing the potential role of cytokines from BCG-stimulated murine splenocytes showed that IL-12 expression preceded that of other cytokines. Experiments subtracting endogenous BCG-driven IL-12 using neutralizing Ab or augmenting its activity with supplemental rIL-12 revealed not only that IL-12 plays a dominant role in IFN-gamma induction but also that it is normally dose limiting. A striking increase in IFN-gamma production could be generated in both mouse and human immunocompetent cell culture by the addition of even a small amount of rIL-12. Moreover, this same synergistic effect could be replicated during in vivo administration of BCG plus rIL-12 into the mouse bladder and was observed in a patient receiving intravesical combination therapy. In costimulation cultures, this synergy appeared to partially rely on IL-18 and IL-2 and could be down-regulated by IL-10. This suggests that a dynamic interplay between Th1 and Th2 cytokines is responsible for net IFN-gamma production. The ability of supplemental exogenous IL-12 to strongly shift this balance toward Th1 provides an immunological basis for using it in conjunction with intravesical BCG for bladder cancer immunotherapy.  (+info)

(5/242) Primary lymphoma of the bladder treated successfully with mitozantrone gel.

We describe a young man who presented with a short history of painless haematuria. Subsequent investigations and biopsy of lesions found in his bladder at cystoscopy confirmed the diagnosis of primary lymphoma of the bladder. Computed tomography studies confirmed the disease was localised to his bladder. Unfortunately, the tumour was not eradicated by radiotherapy. However, it was successfully treated with intravesical mitozantrone given in a novel gel formation. Three years after diagnosis the patient remains well with no evidence of recurrence.  (+info)

(6/242) Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595.

PURPOSE: More effective intravesical agents are required to limit the recurrence and progression of superficial bladder cancer. This study assessed the ability of copper-67 ((67)Cu)-C595 murine antimucin monoclonal antibody to bind selectively to superficial bladder tumors when administered intravesically, with a view to its development for therapy. PATIENTS AND METHODS: Approximately 20 MBq of (67)Cu-C595 monoclonal antibody was administered intravesically to 16 patients with a clinical indication of superficial bladder cancer. After 1 hour, the bladder was drained and irrigated. Tissue uptake was assessed by imaging and by the assay of tumor and normal tissues obtained by endoscopic resection. RESULTS: Tumor was correctly identified in the images of 12 of 15 patients who were subsequently found to have tumors. Assay of biopsy samples at 2 hours showed a mean tumor uptake of 59.4% of the injected dose per kilogram (SD = 48.0), with a tumor-to-normal tissue ratio of 14.6:1 (SD = 20). After 24 hours (n = 5), this decreased to 4.3% of the injected dose per kilogram (SD = 2.9), with a tumor-to-normal tissue ratio of 1.8:1 (SD = 0.8). CONCLUSION: This study indicates a promising method for the treatment of superficial bladder cancer. Although the mean initial tumor uptake was high, effective therapy of bladder tumors will require an increased retention of the cytotoxic radionuclide in tumor tissue.  (+info)

(7/242) Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model.

Using a novel orthotopic MBT-2 murine bladder tumor model, we evaluated the feasibility of intravesical gene therapy utilizing a cationic liposome, DMRIE/DOPE. Superficial bladder tumors were consistently established by intravesical instillation of 5x10(5) MBT-2 cells in syngeneic C3H female mice. In situ gene transfer to bladder tumors was accomplished via intravesical instillation of plasmid DNA/DMRIE/DOPE lipoplex. Beta-Galactosidase (beta-gal) gene expression was preferentially evident in bladder tumors and was present for at least 7 days after a single 30 min in situ transfection. Murine interleukin-2 (IL-2) gene was used for treatment of 3-day-old pre-established bladder tumors. Forty percent of animals treated with IL-2 gene were completely free of tumors by 60 days following the initial tumor implantation, while all control groups treated with beta-gal gene died. Those animals initially cured of pre-established tumors were completely resistant to a subsequent tumor re-challenge and their splenocyte-derived cytotoxic T lymphocytes were shown to be specific to MBT-2 cells, indicating that immunological memory against MBT-2 tumors was elicited by the treatment. These results demonstrate the possibility of an effective clinical application of this in situ intravesical IL-2 gene delivery system to high-risk superficial bladder tumors, obviating a need for tumor procurement and ex vivo gene transfer.  (+info)

(8/242) Mechanisms of action of intravesical bacille Calmette-Guerin: local immune mechanisms.

The local immune response to mycobacteria is complex, but mycobacterial antigen presentation by phagocytes to T helper cells is the pivotal interaction. Bacille Calmette-Guerin (BCG) vaccination is associated with the development of antituberculosis immunity but not necessarily with antitumor immunity. Animal studies have shown that an intact host immune system is required for the antitumor activity of BCG. Immunosuppressed and, particularly, T cell-depleted individuals fail to respond to BCG immunotherapy. Clinical and laboratory evidence suggest that the antitumor activity is concentrated at the site of BCG administration, which reinforces the view that local immune mechanisms are responsible for this phenomenon.  (+info)

*  Bladder cancer
Di Stasi SM, Riedl C (June 2009). "Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle ... April 2009). "Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the ... Alfred Witjes J, Hendricksen K, Gofrit O, Risi O, Nativ O (June 2009). "Intravesical hyperthermia and mitomycin-C for carcinoma ... page needed] Witjes JA, Hendricksen K (January 2008). "Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a ...
*  Interstitial cystitis
... intravesical bacillus Calmette Guerin, intravesical resiniferatoxin), high-pressure and long-duration hydrodistention, and ... "Policy Interpretation Ruling Titles II and XVI: Evaluation of Interstitial Cystitis". Social Security Administration. Archived ... Tyagi P, Kashyap MP, Kawamorita N, Yoshizawa T, Chancellor M, Yoshimura N (January 2014). "Intravesical liposome and antisense ...
*  Mucoadhesion
Intravesical drug administration is the delivery of pharmaceuticals to the urinary bladder through a catheter. This route of ... Consequently, direct administration through the fibrous tunic is common. This is made difficult due to the numerous defense ... With a 0.1-0.7 mm thick mucus layer, the oral cavity serves as an important route of administration for mucoadhesive dosages. ... With an active surface area of 160 cm2, the nasal cavity is another noteworthy route of mucoadhesive administration. Due to the ...
*  Route of administration
... total parenteral nutrition Intravesical infusion is into the urinary bladder. intravitreal, through the eye Subcutaneous (under ... Strictly enteral administration (directly into the intestines) can be used for systemic administration, as well as local ( ... extra-amniotic administration, between the endometrium and fetal membranes nasal administration (through the nose) can be used ... Parenteral administration generally acts more rapidly than topical or enteral administration, with onset of action often ...
*  Thiotepa
In 1959, thiotepa was registered with the Food and Drug Administration (FDA) as a drug therapy for several solid cancers. On ... Thiotepa is used as intravesical chemotherapy in bladder cancer. It may be used prophylactically to prevent seeding of tumor ... "Urgent, thioTEPA update" (PDF). Food and Drug Administration. Adienne Pharma & Biotech. 5 April 2011. Retrieved 25 November ... For intravesical use, thiotepa is given in 30 mg doses weekly, for four to six weeks. Efficacy in tumor control may reach 55 ...
*  Apaziquone
After administration of apaziquone directly into the urinary bladder (intravesically), the drug and its active metabolite were ... October 2006). "Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer". J. Urol. 176 (4 Pt 1 ... The U.S. Food and Drug Administration (FDA) has granted Fast Track review status to apaziquone for this indication. "UvA ...
*  Valrubicin
It was originally launched as Valstar in the U.S. in 1999 for intravesical therapy of Bacille Calmette-Guérin (BCG)-refractory ... Food and Drug Administration News. The MQN Weekly Bulletin, Jan. 11, 2008 "Endo Pharmaceuticals launches VALSTAR for treating ...
*  Treatment of cancer
In certain cancers, administration of hormone agonists, such as progestogens may be therapeutically beneficial. Angiogenesis ... Contemporary methods for generating an immune response against tumours include intravesical BCG immunotherapy for superficial ... Other problems include route of administration, maintenance of stability and activity and targeting at the tumor vasculature. ... Food and Drug Administration. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533873.htm Agrelo R, Cheng WH, ...
*  Transurethral resection of the prostate syndrome
Concurrently the slow administration of intravenous diuretics such as furosemide can correct the sodium by diuresis, however ... The patient should be kept horizontal, as assuming the Trendelenburg position (head tilt down 20°) reduces the intra-vesical ...
*  Sodium hyaluronate
"Filling in Wrinkles Safely". U.S. Food and Drug Administration. 2016-12-20. Wickens JM1, Alsaab HO2, Kesharwani P3, Bhise K2, ... Boucher, W. S.; Letourneau, R.; Huang, M.; Kempuraj, D.; Green, M.; Sant, G. R.; Theoharides, T. C. (2002). "Intravesical ... "Soft Tissue Fillers Approved by the Center for Devices and Radiological Health". U.S. Food and Drug Administration. 2015-07-27 ...
*  Thiomer
In case of oral administration this 'enzymatic barrier' is even more pronounced as an additional degradation caused by ... "Development of pre-activated α-cyclodextrin as a mucoadhesive excipient for intra-vesical drug delivery". Int. J. Pharm. 534 (1 ... Madgulkar, AR; Bhalekar, MR; Kadam, AA (2017). "Improvement of oral bioavailability of lopinavir without co-administration of ... "Biodistribution and pharmacokinetics of EGFR-targeted thiolated gelatin nanoparticles following systemic administration in ...
*  Tata Memorial Centre
Its a fully funded Grant-in-Aid Institution of Department of Atomic Energy, which also oversees the administration of institute ... and the role of urinary cytokines in intravesical BCG therapy in superficial bladder cancer. The biology of HIV-2, the virus ...
*  BCG vaccine
However, it is important to note an abscess is not always associated with incorrect administration, and it is one of the more ... Houghton, BB; Chalasani, V; Hayne, D; Grimison, P; Brown, CS; Patel, MI; Davis, ID; Stockler, MR (May 2013). "Intravesical ... Nonetheless, the buttock is an alternative site of administration because it provides better cosmetic outcomes. BCG vaccine ... Lamm DL, Blumenstein BA, Crawford ED (1991). "A randomized trial of intravesical doxorubicin and immunotherapy with bacille ...
OBJECTIVE: To determine, in a phase I trial, the local and systemic toxicity and pharmacodynamics of intravesical gemcitabine in patients with superficial bladder cancer. PATIENTS AND METHODS: Twelve patients with histologically confirmed carcinoma localized to the bladder wall (stage T1 or Ta) resistant to previous administration of anticancer drugs and/or of bacille Calmette-Guerin were enrolled. They initially received intravesical gemcitabine starting at 500 mg and increased in 500 mg increments to 2000 mg. Three patients were treated at each dose level. RESULTS: There was no evidence of systemic toxicity and local toxicity was minimal. A pharmacological evaluation showed that gemcitabine was undetectable in plasma and its inactive metabolite (2,2-difluorodeoxyuridine) was present at a mean (SD) concentration of 1.39 (1.05) mumol/L Deoxycytidine kinase was present in tumour tissue samples, and its activity was 27.3 (12.6) pmol/h/mg tissue; deoxycytidine deaminase activity varied from ...
This study investigated the safety of intravesical administration of a second-generation ultrasound contrast agent sulfur hexafluoride for the diagnosis of
Clinical Application of the Adenosine Triphosphate-based Response Assay in Intravesical Chemotherapy for Superficial Bladder Cancer Adenosine triphosphate;chemotherapy response assay;superficial bladder cancer; Objective: To investigate correlations between adenosine triphosphate chemotherapy response assay (ATP-CRA) and clinical outcomes after ATP-CRA-based chemotherapy for drug selection in patients receiving intravesical chemotherapy to prevent recurrence of superficial bladder cancer after surgery. Methods: The chemosensitivities of 12 anticancer drugs were evaluated, including 5-Fu ADM, and EPI, using ATP-CRA and primary tumor cell culture in 54 patients. In addition, a further 58 patients were treated according to clinical experience. Differences in post-chemotherapeutical effects between drug sensitivity assay and experience groups were compared. Results: The evaluable rate of the test was 96.3%, the clinical effective rate was 80.8%, the sensitivity rate was 97.6% (41/42), the specificity was
Bladder cancer is the fourth and eighth most common malignancy among men and women, respectively. About 75% of bladder cancers are diagnosed as non muscle-invasive and according to specific tumor-stage and grade characteristics, intravesical immunotherapy with Bacillus Calmette-Guérin (BCG) is used to prevent recurrence and/or progression. However, BCG immunotherapy is associated with significant adverse events and treatment failure may occur in 30-40% of cases, hence the necessity for alternative therapies. In an orthotopic MB49 mouse bladder cancer model, another bacterial vaccine (Ty21a/Vivotif) turned out to be more effective than BCG for inducing tumor regression and mice survival upon intravesical instillation; and potentially safer because Ty21a bacteria did not infect/persist in any mice tissues nor in human bladder explants or cell lines, in contrast to BCG. Ty21a/Vivotif has been used in the last 30 years in millions of individuals as an oral typhoid vaccine with a high safety record. ...
Non-muscle-Invasive Bladder cancer is mainly treated by tumor resection (Trans Urethral Resection - TUR), followed by series of intravesical instillations of prophylactic chemotherapeutic drugs as Mitomycin C (MMC).This treatment approach is limited due to rapid dilution the chemotheraputic drug by the incoming urine and clearance by urination.. TheraCoat core technology is based on a reverse thermal (low viscosity at 5°C) degradable gel (TC-3)for MMC retention in the urinary bladder.. Prior to instillation, the TC-3 hydrogel,in a liquid state, is mixed with MMC.TC-3 mixed with MMC is instilled to the bladder by a catheter.Following gel insertion to the bladder, the gel solidifies and forms a drug reservoir inside the bladder. Upon contact with urine the gel dissolves and is cleared out from the bladder.. Intravesical MMC using TheraCoat gel is expected to increase treatment efficiency due to prolongation of treatment duration and consequently improving bladder exposure to MMC. ...
Find the best intravesical chemotherapy doctors in Delhi NCR. Get guidance from medical experts to select intravesical chemotherapy specialist in Delhi NCR from trusted hospitals - credihealth.com
There was no evidence of systemic toxicity and local toxicity was minimal. A pharmacological evaluation showed that gemcitabine was undetectable in plasma and its inactive metabolite (2′,2′-difluorodeoxyuridine) was present at a mean (sd) concentration of 1.39 (1.05) µmol/L. Deoxycytidine kinase was present in tumour tissue samples, and its activity was 27.3 (12.6) pmol/h/mg tissue; deoxycytidine deaminase activity varied from undetectable to 616 pmol/h/mg tissue. ...
Intravesical administration of the cytotoxic drug doxorubicin is a common treatment for superficial carcinoma of the bladder, but it is associated with significant urological adverse effects. The aim of this study was to identify doxorubicin-induced changes in the local mechanisms involved in regulating bladder function. As a model of intravesical doxorubicin administration in patients, doxorubicin (1 mg/mL) was applied to the luminal surface of porcine bladders for 60 min. Following treatment, the release of urothelial/lamina propria mediators (acetylcholine (Ach), ATP and prostaglandin E2 (PGE2) and contractile responses of isolated tissue strips was investigated. Doxorubicin pretreatment did not affect contractile responses of detrusor muscle to carbachol, but did enhance neurogenic detrusor responses to electrical field stimulation (219 % at 5 Hz). Contractions of isolated strips of urothelium/lamina propria to carbachol were also enhanced (30 %) in tissues from doxorubicin pretreated bladders.
Intravesical treatment of superficial bladder cancer is done to prevent tumor recurrence after successful local surgical resection and to eradicate residual disease. Various intravesical chemotherapeutic agents, such as thiotepa, doxorubicin, and mitomycin, have been the therapeutic treatment of choice for years; however, these agents achieved short remissions with a net durable benefit for ∼7% to 14% of patients ( 26). More unconventional forms of treatment, such as immunotherapy, were introduced in the last few decades due to unsatisfactory chemotherapy results, where one of the most successful therapies for superficial bladder cancer and carcinoma in situ of the bladder is intravesical administration of Mycobacterium bovis bacillus Calmette-Guerin (BCG; ref. 27). However, this therapy has also displayed limited success because 25% to 40% of the patients never respond to BCG ( 28, 29). The development of therapeutic regimens that offer potent tumoricidal activity but no toxic side effects to ...
Long-term results were analyzed in terms of tumor progression and survival in patients with superficial bladder cancer who were enrolled in the second intravesical chemoprophylactic study of the...
Intravesical therapy is a treatment that is put directly into the bladder (through a catheter) rather than being given by mouth or injected into a vein.
Background. The use of nanoparticles has shown great therapeutic potential, but delivery and clearance concerns have limited their use systemically. Intravesical instillation of nanoparticles in the urinary bladder provides a unique administration route to treat superficial bladder cancer. We examined the anti-tumor effect of epidermal growth factor receptor (EGFR)-directed gold nanorods combined with photothermal treatment in a superficial bladder cancer model.. Methods. A novel orthotopic nu/nu murine xenograft model was established through intravesical instillation of T24 human bladder cancer cells labeled with Luciferase. After confirmation of positive tumor cell implantation via bioluminescence, gold nanorods linked to the anti-EGFR antibody C225 were instilled into the bladder cavity. The nanorods were specifically fashioned to respond to near infrared (NIR) light, which was externally administered via an 808 nm diode laser to the bladder. A safe and effective regimen of in vivo ...
The purpose of this research study is to test the safety and tolerability of an experimental drug, Chemophase, a combination of recombinant human hyalur
Intravesical BCG Treatment   BCG placed into the bladder following the diagnosis of bladder cancer has been shown to decrease the rate of tumour recurrence but more importantly it decreases the rate of tumour progression - ie: it can prevent a superficial cancer from turning into a more serio
P.I.: Satia, Jessie A Department: Nutrition and Epidemiology Title: Effect of Supplemental Omega-3 Fatty Acids in Patients with Superficial Bladder Cancer After Transurethral Resection: A Randomized Trial
Introduction: Intravesical immunotherapy with mycobacterium bovis baccillus Calmette-Guerin (BCG) has been the standard of care for high grade non-muscle invasive bladder tumors for nearly 40 years. While BCG has been successful at lowering recurrence rates and preventing progression, it does not engage adaptive memory and is associated with recurrence rates as high as 50%. Thus the search for treatment strategies that promote a durable anti-tumor memory response is warranted.. One such strategy developed by our group is the intravesical administration of a simple coformulation of the TH1 polarizing cytokine interleukin-12 (IL-12) and the biopolymer chitosan (chitosan/IL-12). Chitosan is not bioactive but is cationic and viscous in solution and acts as a delivery vehicle for IL-12. It is presumed to enhance three aspects of delivery. 1) Chitosans positive charge interacts with the urotheliums tight junctions to transiently increase its permeability. 2) Mucoadhesive forces between the ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohm RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000; 163: 1124-9 ...
The ability of the immune system to recognize and eradicate cancer was first postulated in the 19th century; however, proof of principle remained elusive until the 20th century. The effect of infection on tumor regression was observed as early as 1884 by Anton Chekov (1); following this, William Coley developed a mixture of killed bacteria that were used to treat various types of cancer between the 1890s and 1960s with mixed clinical benefit. In addition, the concept of using bacterial elements was validated with Food and Drug Administration (FDA) approval of intravesical administration of BCG, which is an FDA-approved therapy that leads to nonspecific inflammatory immune responses and clinical benefit for patients with superficial bladder cancer (2). The discovery of the major histocompatibility complex (MHC) and T-cell receptor (TCR) in the 1980s provided insight into T-cell function that led to a number of clinical trials (3,4). Unfortunately, many of the early clinical trials failed due to ...
Patients with non-invasive bladder cancer are often treated with intravesical therapy in order to prevent the recurrence of bladder cancer. Intravesica
Systemic administration of LPS produces pain, inflammation and changes in immune function that mimic septic shock. Many of these effects are mediated by production of cytokines and nitric oxide. During a UTI, attachment of bacteria to the urothelium causes epithelial hyperplasia (Uchida et al., 1989), increase in cytokines (Hedges et al., 1992; Ko et al., 1993;Svanborg et al., 1994; Davidoff et al., 1997), influx of neutrophils (Fukushi and Orikasa, 1981) and induction of iNOS (Wheeler et al., 1997). Intravesical instillation of LPS in rats after pretreatment with protamine sulfate also causes urothelial shedding and an influx of neutrophils (Stein et al., 1996). In our present experiments, we show that LPS induces significant increases in mRNA message for the cytokines, IL-6 and IL-10, and for iNOS in the bladder of rats. Bladder iNOS activity, defined as Ca++-independent NOS activity, also is induced within 4 hr after intravesical instillation of LPS, with resultant increases in urinary NO ...
Increase in bladder mucosal permeability can be reproduced by intravesical administration of protamine sulfate (PS); however, the influence of PS once administered into the bladder disappears within several days. We developed a chronic animal model of urothelial injury using PS. Insertion of a polyethylene catheter through the bladder dome was performed in female Wistar rats. The other end of the catheter was connected to an osmotic pump for continuous delivery of PS or vehicle for 2 wk. Urinary frequency (UF) and voided volume (VV) were measured in the metabolic cage. The fifth group of rats received a high dose of PS (10 mg/ml) for 2 wk and were followed for a further 2 wk without PS. The sixth group received a high dose of PS for 2 wk and loxoprofen (0.1 mg.kg(-1).day(-1)) for 4 wk. UF was increased, and VV was reduced in rats treated with a high dose of PS but not changed in rats treated with a vehicle or a low dose of PS (1 mg/ml). UF was further increased in the fifth group, while unchanged in the
Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting [email protected] All previous versions of the manuscript and all author responses to the reviewers are also available.. You can find further information about the peer review system here.. ...
People with intermediate-risk non-muscle-invasive bladder cancer should be offered a course of at least six doses of chemotherapy. The liquid is placed directly into your bladder, using a catheter, and kept there for around an hour before being drained away.. You should be offered follow-up appointments at three months, nine months, 18 months, then once every year. At these appointments, your bladder will be checked using a cystoscopy. If your cancer returns within five years, youll be referred back to a specialist urology team.. Some residue of the chemotherapy medication may be left in your urine after treatment, which could severely irritate your skin. It helps if you urinate while sitting down and that youre careful not to splash yourself or the toilet seat. After passing urine, wash the skin around your genitals with soap and water.. If youre sexually active, its important to use a barrier method of contraception, such as a condom. This is because the medication may be present in your ...
Background: Current treatment options for metastatic UC remain limited, and tolerability is a concern in many patients. Alterations in the fibroblast growth factor receptor (FGFR) pathway are implicated in development of non-muscle-invasive bladder cancer; FGFR3 mutations or FGFR translocations are present in ∼10-20% of patients with metastatic UC. Treatment with pan-FGFR (FGFR1-4) inhibitor JNJ-42756493 resulted in promising antitumor activity in a phase 1 trial in patients with advanced solid tumors, including 3 partial responses among 8 patients with UC (Tabernero J, et al. J Clin Oncol. 2015). Safety was manageable and as anticipated with a potent FGFR inhibitor. This phase 2 open-label study of JNJ-42756493 (NCT02365597) is being conducted to determine efficacy and safety of 2 different dose regimens in patients with metastatic or unresectable UC with specific FGFR translocations or mutations.. Methods: Eligible patients must have disease progression following chemotherapy for metastatic ...
In this work, we present a novel use of an EGFR-directed fusion protein with a modified DT. Bladder cancer frequently overexpresses EGFR on the luminal surface, whereas such expression is uncommon on the normal urothelium. Using an orthotopic, xenograft model of bladder cancer, we showed a difference in the elimination of the implanted tumor after 2 weeks of intravesical treatment with DAB389EGF, as compared with the control DT chimeric protein (DAB388GM-CSF). Importantly, in immunocompetent mice, there was clear, generalized toxicity with the intravenous DAB389EGF treatment, but there was no evidence of histologic or generalized toxicity in the intravesically treated mice at equal doses.. While targeted agents have made significant inroads into the clinical management of most common cancer types, there is no integration of such agents into the routine treatment of urothelial carcinoma. Importantly, in most cases, the use of inhibiting a particular molecular pathway is dependent on "pathway ...
Consumer information about the medication VALRUBICIN - INTRAVESICAL (Valstar), includes side effects, drug interactions, recommended dosages, and storage information. Read more about the prescription drug VALRUBICIN - INTRAVESICAL.
This phase I trial investigated the tolerability and pharmacokinetics of a single intravesical instillation of mitomycin formulated with
The most effective form of immunotherapy for solid tumours is still poorly understood. The main risks from superficial bladder cancer are that it may recur or that it may progress to invasive disease with a high mortality. Immunotherapy with live BCG vaccine was shown to be an effective treatment as long ago as 1976,1 and the vaccine is still the only intravesical agent to have been shown to reduce both of these risks.2. Factors that increase the risk of progression are high tumour grade, invasion of the lamina propria, and the presence of carcinoma in situ.3 The main indications for the use of BCG vaccine in Britain are treatment of carcinoma in situ of the bladder; treatment of residual superficial papillary tumour; and prophylaxis against recurrence of superficial tumours and against progression after resection of a tumour.. No one questions the use of BCG vaccine for diffuse carcinoma in situ. This condition is difficult to eradicate by resection--indeed, if treated by surgery alone it ...
The concept of using activation of the innate immune system and an inflammatory response against a bacterial component to instigate an antitumor response was studied in the 1960s, which led to the development of intravesical bacillus Calmette-Guérin, now used in the treatment of superficial bladder cancer. Over the following decades, the promise of immunotherapy ebbed and flowed until a couple of decades ago, when researchers saw promise in T-cell activation, paving the way for a revival of immunotherapy. Today, one of the most exciting areas in immunotherapy is checkpoint blockade.. The ASCO Post recently spoke with James P. Allison, PhD, who received the 2015 Lasker-DeBakey Clinical Medical Research Award for his pioneering work in enabling T cells to attack cancer cells by removing "checkpoints" that normally inhibit T-cell activity.. A Career-Changing Period. Please tell the readers a bit about your career and your current position.. I came from a small town in south Texas and received both ...
New intravesical treatment approaches for bladder cancer are needed as currently approved treatments show several side effects and high tumor recurrence rate. Our study used MB49 murine urothelial carcinoma model to evaluate oxygen encapsulated cellulosic nanobubbles as a novel agent for imaging and ultrasound guided drug delivery. In this study, we show that oxygen nanobubbles (ONB) can be propelled (up to 40 mm/s) and precisely guided in vivo to the tumor by an ultrasound beam. Nanobubble velocity can be controlled by altering the power of the ultrasound Doppler beam, while nanobubble direction can be adjusted to different desired angles by altering the angle of the beam ...
According to our present knowledge the surgical intervention in the treatment of bladder cancer is essential, but some non-surgical treatment methods play an indispensable role as well. Superfi cial (non-muscle-invasive) form of bladder cancer can be treated by intravesical chemotherapy or BCG instillation, radiotherapy; the muscle-invasive forms of this tumour (≥pT2a) need neoadjuvant, adjuvant chemotherapy, radiotherapy or radio-chemotherapy. In case of metastatic disease (or locally advanced, recurrent disease) the treatment regimen consist of chemotherapy (given as fi rst line or second line), palliative radiotherapy, interventional methods, radio-isotope therapy and symptoms relief drugs. We present each of the therapeutic modalities and their indications category based on the ESMO and NCCN guidelines.. ...
43. Tingsheng Lin, Xiaozhi Zhao, Yifan Zhang, Huibo Lian, Junlong Zhuang, Qing Zhang, Wei Chen, Wei Wang, Guangxiang Liu, Suhan Guo, Jinhui Wu,*, Yiqiao Hu,* and Hongqian Guo* Floating Hydrogel with Self-Generating Micro-Bubbles for Intravesical Instillation Materials 2016, 9, 1005 ...
Treatment options for an inflamed bladder include bladder instillation, bladder distention, surgery and nerve stimulation, according to WebMD. Medications are also used to help treat the...
Anyone? Discount vendors seem to be out of stock and prices are rising. New brands (Manna, Theracyn), etc. Any info on what we should be buying and where? I used to buy for 13 dollars, now they are anywhere from 22 to 28 dollars. Last, any information on a clinical trial for bladder instillation on humans? Some here have been using this for 5 years or more, it seems that the market for instillation would be substantial, I am curious as to why there is no information on a clinical trial.
Visit your doctor for checks on your progress. This drug may make you feel generally unwell. Contact your doctor if your symptoms last more than 2 days or if they get worse. Call your doctor right away if you have a severe or unusual symptom.. Infection can be spread to others through contact with this medicine. To prevent the spread of infection follow your doctors directions carefully after treatment. For the first 6 hours after each treatment, sit down on the toilet to urinate. After urinating, add 2 cups of bleach to the toilet bowl and let set for 15 minutes before flushing. Wash your hands before and after using the restroom.. Drink water or other fluids as directed after treatment with this medicine.. Do not become pregnant while taking this medicine. Women should inform their doctor if they wish to become pregnant or think they might be pregnant. There is a potential for serious side effects to an unborn child. Talk to your health care professional or pharmacist for more information. Do ...
Two general strategies have been used to target myelomonocytic cells in tumors: inhibition of recruitment and/or elimination (the latter achieved by direct killing) and reeducation (Fig. 3). The plasticity and flexibility of myelomonocytic cells (Hagemann et al., 2008; Mosser and Edwards, 2008) provides a basis for strategies aimed at "resetting" TAMs in an antitumor mode. Agents in this broad category include the classic Th1 cytokine IFNγ, which early on showed objective responses in minimal residual ovarian cancer (Colombo et al., 1992; Pujade-Lauraine et al., 1996); bacterial products, with intravesical BCG being part of the armamentarium in bladder cancer; TLR agonists (e.g., CpG oligonucleotides, which are undergoing preclinical and clinical evaluation [e.g., Iida et al., 2013]); and antibodies that activate via the CD40 molecule. A fully human CD40 agonist antibody CP-870,893 was administered in combination with gemcitabine chemotherapy to 21 patients with advanced pancreatic cancer, with ...
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
Drug information provided by: Micromedex. While you are being treated with BCG, and for 6 to 12 weeks after you stop treatment with it, avoid contact with people who have tuberculosis. If you think you have been exposed to someone with tuberculosis, tell your doctor. ...
... This report studies Intravesical Bacillus Calmette in Global market, especially - Market research report and industry analysis - 10750434
The Dangers of Using Mitomycin-C The potent agent that has the power to banish haze may be able to make endothelial cells disappear, as well.. Mitomycin is FDA approved for the...Mitomycin C: mechanism of action, usefulness and limitations.. Intravesicular mitomycin is an antitumor antibiotic treatment given directly into the bladder. However, it can occur with any instillation.The purpose of this study is to compare the bladder cancer treatments, Mitomycin C (MMC) and Bacillus Calmette Guerin (BCG), to find out which is better.Mitomycin - Drug Info, Side Effects, Research, Clinical Trials. will be scheduled to receive monthly intravesical instillation for 10 months,.Mitomycin C is given as a chemotherapy,. mitomycin c intravesical Instillation. here in video we have instilled 40 mg of Mitomycin,.Mitomycin C is a mitomycin that is used as a chemotherapeutic agent by virtue of its antitumour. as well as by bladder instillation for superficial bladder tumours.. EAUN15 Guideline Intravesical ...
Non-muscle invasive bladder cancer is the most common type of bladder cancer in Western countries. The glycosaminoglycan (GAG) layer at the bladder surface non-specifically blocks the adherence of bacteria, ions and molecules to the bladder epithelium and bladder cancer cells express CD44 that binds GAG. Currently, there are few options other than cystectomy for the management of non-muscle invasive bladder cancer with intravesical chemotherapy using several drugs such as gemcitabine (GEM) and mitomycin-C (MMC) with poor prophylactic activity. In this study, we investigated the effects of the GAG chondroitin sulphate (CS) on the growth inhibition of human bladder cancer cell lines HT-1376 and effects of the combination between GEM or MMC with CS. We have found that CS, MMC and GEM induced 50% growth inhibition at 72 h. Therefore, we have evaluated the growth inhibition induced by different concentration of CS in combination with MMC or GEM, respectively, at 72 h. We have observed, at Calcusyn ...
Introduction. On May 18, 2016, atezolizumab became the first anti-PD-L1 inhibitor to gain FDA approval for use in patients with advanced urothelial carcinoma. Approval of an additional 4 anti-PD-1/ PD-L1 inhibitors would follow.1 These exciting new treatments take advantage of interactions between cancer cells and their hosts immune system, thereby offering patients an alternative to cytotoxic therapies. Widespread use of these novel agents requires that clinicians gain familiarity with the growing field of immunotherapy. In this review, we discuss basic concepts for understanding the immune systems interactions with malignant cells, as well as report on the currently available immunotherapies in the treatment of bladder cancer.. The susceptibility of bladder cancer to immune-mediated destruction is not a new concept, as demonstrated by the use, decades ago, of Bacillus Calmette-Guérin (BCG) by urologists for non-muscle-invasive bladder cancer. Based on an observation that tuberculosis ...
It is estimated that the incidence of bladder cancer in the United States in 1999 will be ∼54,200 new cases with an expected mortality of 12,100 (1) . In men, bladder cancer remains the fourth most common malignancy and will account for 6% of all cancer cases, whereas in women, it is the eighth most common malignancy and will account for 3% of all cancers (1) . Furthermore, the incidence of bladder cancer has increased in the United States by 36% from 1956 to 1990 (2) . Presently, 74% of bladder cancers are superficial at initial diagnosis, 18% are advanced but confined to the pelvis, whereas only 3% have metastasized (2) . However, up to 30% of all patients with superficial disease will develop muscle invasive tumors within 5 years (3 , 4) .. Treatment of superficial disease aims to eradicate existing disease and to prevent tumor recurrence and/or progression to muscle invasion and metastasis. Patients treated by transurethral resection alone have only a 49% chance of remaining free of ...
The investigators intend to evaluate the safety and toxicity profile of intravesically administered multidrug regimen of Cabazitaxel, Cisplatin and Gemcitabine in treatment refractory Transitional Cell Carcinoma.The investigators propose to conduct a combined phase I trial to assess the safety, toxicity, and efficacy of a novel multidrug intravesical regimen consisting of Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the treatment of BCG resistant non-muscle invasive urothelial carcinoma of the bladder. This phase I trial will have a combined dose and cycle-escalation scheme with enrollment of up to 24 patients.
Mitomycin C is a mitomycin that is used as a chemotherapeutic agent by virtue of its antitumour activity. It is given intravenously to treat upper gastro-intestinal cancers (e.g. esophageal carcinoma), anal cancers, and breast cancers, as well as by bladder instillation for superficial bladder tumours. It causes delayed bone marrow toxicity and therefore it is usually administered at 6-weekly intervals. Prolonged use may result in permanent bone-marrow damage. It may also cause lung fibrosis and renal damage. Mitomycin C has also been used topically rather than intravenously in several areas. The first is cancers, particularly bladder cancers and intraperitoneal tumours. It is now well known that a single instillation of this agent within 6 hours of bladder tumor resection can prevent recurrence. The second is in eye surgery where mitomycin C 0.02% is applied topically to prevent scarring during glaucoma filtering surgery and to prevent haze after PRK or LASIK; mitomycin C has also been shown to ...
INTRODUCTION AND HYPOTHESIS: The glycosaminoglycan hyaluronic acid (HA) protects the urothelium; damage may increase bacterial adherence and infection risk. This study evaluated the effect of intravesical HA in recurrent bacterial cystitis (RBC). MET
Bladder cancer poses a serious public health challenge, given the high rate of incidence and the cost for managing this disease. Muscle-invasive tumors are the most difficult to treat and pose a significant threat to life, due to their metastatic nature. Approximately 80% of human bladder cancers are non-muscle invasive when first diagnosed and are usually treated by transurethral tumor resection. But 50% to 80% of patients experience cancer recurrence. To prevent or delay tumor recurrence, intravesical therapy with Bacillus Calmette-Guerin (BCG) is frequently used as an adjunctive after TUR. Other agents such as mitomycin, gemcitabine, and pirarubicin are being investigated clinically (27-29). However, BCG may not be effective in all patients, have significant side effects such as infection by BCG, and require urethral catheterization. Therefore, there is a need to identify agents for primary and secondary prevention of bladder cancer. There has been significant progress in the molecular ...
You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our cookies policy. ...
LATERAL ARTICULATION ANCHORS FOR CATHETERS AND OTHER USES | CATHETER WITH MULTI-FUNCTIONAL CONTROL HANDLE HAVING LINEAR MECHANISM | INPUT AND ARTICULATION SYSTEM FOR CATHETERS AND OTHER USES | INTRAVESICAL DRUG DELIVERY METHODS AND DEVICES | Intraperitoneal Chemotherapy Medical Devices, Kits, and Methods |
Muthiah Manoharan is the author of this article in the Journal of Visualized Experiments: Orthotopic 방광 종양 모델 및 Intravesical saRNA 트리 트먼트의 평가
OBJECTIVE: To describe a case of epididymo-orchitis that developed four years after treatment with intravesical bacillus Calmette-Guérin (BCG) and to review the incidence of this adverse effect. DATA SOURCES: Information about the patient was obtain
Horvath, A, Simpson, GR, Coffin, RS, Mostafid, H and Pandha, H (2009) NOVEL INTRAVESICAL THERAPY FOR NON MUSCLE INVASIVE BLADDER CANCER: COMBINATION OF A FUSOGENIC GLYCOPROTEIN, PRO-DRUG ACTIVATION AND ONCOLYTIC HERPES SIMPLEX VIRUS ...
Patients are only referred to this clinic by Consultant Urologists within Sydney Local Health District (SLHD).. To make an appointment: Ph. 9767 6410. Fax. 9767 6751 ...
Treating Interstitial Cystitis/Painful bladder syndrome (IC) poses a challenge to all practitioners. What works for some might not work for others. IC is characterized by urinary frequency, urinary urgency, nocturia combined with bladder and pelvic pain. The different causes of IC (i.e. allergy, genetics, injury from recurrent infection, etc.) may account for the variability in treatment response. Treatments include dietary modifications and physical therapy, oral agents like Elmiron and amitriptyline, intravesical injections, and bladder hydrodistention in the operating room.. Given the urinary frequency component of IC, I have often wondered if treating it as a terrible case of overactive bladder (OAB) would work. I have prescribed OAB medications for my IC patients in the past with disappointing results. My usual go-to treatment for IC has been DMSO bladder instillations or bladder cocktails. Still, those tend to fall short for me. I want a cure! I want complete relief for my ...
Photodynamic diagnosis (PDD) is a technique that enhances the detection of tumors during cystoscopy using a photosensitizer which accumulates primarily in cancerous cells and will fluoresce when illuminated by violetblue light. A disadvantage of PDD is the relatively low specificity. In this retrospective study we aimed to identify predictors for false positive findings in PDD. Factors such as gender, age, recent transurethral resection of bladder tumors (TURBT), previous intravesical therapy (IVT) and urinary tract infections (UTIs) were examined for association with the false positive rates in a multivariate analysis. Data of 366 procedures and 200 patients were collected. Patients were instilled with 5-aminolevulinic acid (5-ALA) intravesically and 1253 biopsies were taken from tumors and suspicious lesions. Female gender and TURBT are independent predictors of false positives in PDD. However, previous intravesical therapy with Bacille Calmette-Guérin is also an important predictor of false ...
Approximately 70 percent of new urothelial (formerly called transitional cell) bladder cancer cases are classified as non-muscle invasive. Non-muscle invasive bladder cancer includes Ta, T1 (submucosal invasive) tumors, and Tis (carcinoma in situ [CI
TY - JOUR. T1 - BCG Immunotherapy Against Non-Muscle Invasive Bladder Cancer. T2 - Recent Results, Current Studies and Future Perspectives. AU - Takeuchi, Ario. AU - Shiota, Masaki. AU - Tatsugami, Katsunori. AU - Yokomizo, Akira. AU - Eto, Masatoshi. PY - 2016/1/1. Y1 - 2016/1/1. UR - http://www.scopus.com/inward/record.url?scp=84979097020&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84979097020&partnerID=8YFLogxK. M3 - Review article. C2 - 27333654. AN - SCOPUS:84979097020. VL - 107. SP - 8. EP - 11. JO - Fukuoka Acta Medica. JF - Fukuoka Acta Medica. SN - 0016-254X. IS - 1. ER - ...
Bladder cancer will kill upward of 170,000 people worldwide this year, but bladder cancer isnt fatal in the bladder. Instead, in order to be fatal the disease must metastasize to faraway sites. The question has been this: does localized, non-muscle invasive (NMI) bladder cancer eventually become the more dangerous, muscle-invasive (MI) form of the disease, or are NMI and MI bladder cancers genetically distinct from the start?. A University of Colorado Cancer Center study published today in the journal Stem Cells shows its the latter: the progenitor cells that create MI bladder cancer are different than the progenitor cells that create NMI bladder cancer. Though these two cancers grow at the same site, they are different diseases.. "This work provides an important new perspective on how we look at bladder cancer biology," says Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center and the studys senior author.. The group including first author Garrett Dancik, PhD, ...
Intravesical Adriamycin treatment was given to 22 patients with carcinoma in situ of the urinary bladder. The treatment schedule consisted of monthly Adriamycin instillations in a dose related to bladder capacity. Endoscopic inspection with multiple bladder biopsies and cytoanalysis of urine was performed after every third instillation. In two patients there was lasting disappearance of the carcinoma in situ. Another 10 patients possibly had a beneficial effect of the treatment. The remaining 10 patients showed persistent malignancy and in 6 of these, progression of carcinoma in situ during Adriamycin treatment necessitated cystectomy or radiotherapy. The histologic and cytologic findings showed distinct variability in most patients, with atypia or even absence of malignant cells often followed by recurrence. Adriamycin was discontinued in four cases because of severe cystitis, and in one case because of an anaphylactoid reaction following instillation of the drug.
Learn about Cysview (Hexaminolevulinate Hydrochloride Intravesical Solution) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications.
Nanoparticle Research is a fundamental component of Nanoscience and Nanotechnology and the Aadibio is developing their study on Nanoparticle.
Learn about interstitial cystitis treatments: OTC, natural treatments, oral meds, bladder instillations, botox, neuromodulation, cyclosporine & more
Side effects of bcg treatment for bladder cancer - Is BCG treatment for bladder cancer the same as chemotherapy? No. Bcg is a topical therapy that is essentially a type of immune based therapy applied only to bladder cells. Traditional chemotherapy is given intravenously and thus all body cells are exposed. Some chemotherapy drugs can be given topically like BCG and probably exert their effect via typical cancer cell-killing compared to immune stimulating effects of BCG similarly administered.
The optimal treatment for urothelial bladder cancer depends upon the cancers stage and grade.Approximately 70 percent of all new cases of bladder cancer are classified as non-muscle invasive, also called superficial bladder cancer. The initial treat
A total of 10 patients with histologically proved carcinoma in situ of the bladder had remission of tumor after topical chemotherapy with doxorubicin hydrochloride for 24 months. Of the 10 patients 3 suffered new areas of carcinoma in situ 9 to 12 months after termination of intravesical chemotherapy. Furthermore, 1 of these 3 patients had a distal ureteral tumor. Fibrosis of the submucosal tissue was observed in every patient but a decrease in bladder capacity was observed in only 1 with prior radiotherapy. ...
for the past 10 yrs Ive had kidney pain off and on. Not ever bad enough to be considered stones. I had a third ovarie sitting right on and crushing my urethra tube. I am aware that my bladder does not completly empty. I had all kinds of test done nothing, but Iam wondering if Im not being tested at the time the current symptoms I have that, that is why nothing shows up. Current sypmtoms are, Oh Im 44 yrs female, feet ankels swelling and rarely all over swelling. Skin sometimes seems yellowish, not eyes. bladder spasms, ureter spasms maybe caused by my past superficial bladder cancer and fibroids in the uterus. bp is 128 0ver 80 and that is a little high for me. Having trouble when speaking remebering what im talking about. Been sleepless then not, usually if I get woke up I cant fall back to sleep. No noturia but have both kinds of incontinece. Sometimes really hungary sometimes not. Iron deficient aneimia. Right now still having fairly normal periods but sometimes heavy on second day and they ...
OBJECTIVE: To characterize the contractile activity that occurs in the bladder during the filling phase of the micturition cycle (non-micturition contractions, NMCs), which generate transient rises in intravesical pressure not associated with urine flow.. MATERIALS AND METHODS: The experiments were conducted using anaesthetized (chloral hydrate) and un-anaesthetized rats. In un-anaesthetized rats bladder contractile activity was measured using an intravesical cannula implanted under full surgical anaesthesia 3 days previously. In the anaesthetized rats the bladder was exteriorized and a cannula inserted through the dome. In these experiments electrical activity within the detrusor was also measured with a suction electrode on the bladder surface. For each rat, the experimental protocol involved filling the bladder at a constant rate (10 mL/h) to evoke micturition cycles, or infusion of a fixed volume and recording made under effective isovolumetric conditions.. RESULTS: In both anaesthetized and ...
EVALUATION OF THE UROVYSION (TM) TEST FOR PREDICTING RECURRENCE AND PROGRESSION IN PATIENTS RECEIVING BCG FOR HIGH GRADE NON-MUSCLE INVASIVE BLADDER CANCER
When adminstering mitomycin intravesically to patients; I draw it up in a 60-cc syringe and then I have someone else assist to pour the solution into a catheter syringe after I catheterize the
BioAssay record AID 387249 submitted by ChEMBL: Agonist activity at dog cloned adrenergic beta3 receptor assessed as inhibition of carbachol-induced increase in intravesical pressure at 10 ug/kg, iv.
The Interstitial Cystitis Clinical Research Network (ICCRN) is a product of two NIDDK programs: the Interstitial Cystitis Database (ICDB) Study and the Interstitial Cystitis Clinical Trials Group (ICCTG). Established in 1991, the ICDB was a 5-year prospective cohort study of more than 600 men and women with symptoms of urinary urgency, frequency, and pelvic pain. The study described the longitudinal changes of urinary symptoms, the impact of IC on quality of life, treatment patterns, and the relationship between bladder biopsy findings and patient symptoms. The ICCTG was established in 1996 as a follow-up to the ICDB study. The clinical trials group developed two randomized, controlled clinical trials of promising therapies, one using oral therapies-pentosan polysulfate sodium (Elmiron) and hydroxyzine hydrochloride (Atarax)-and the other administering intravesical treatment using Bacillus Calmette-Guérin (BCG). BCG is a vaccine for tuberculosis that stimulates the immune system and may have an ...
5120 Study of urothelial tumorigenesis using a transgenic approach has become possible through development of a mouse model using a urothelium-specific gene promoter. We used magnetic resonance (MR) imaging to evaluate the development of superficial bladder cancers in transgenic mice harboring an activated Ha-ras gene (Ha-ras-M) driven by the uroplakin II (UPII) gene promoter. This model, which develops non-invasive papillary transitional cell carcinomas similar to superficial bladder cancers diagnosed in humans, may be useful to test new chemopreventive agents for bladder cancer. MR imaging techniques were developed at M. D. Anderson Cancer Centers Small Animal Cancer Imaging Research Facility using a Signa 1.5 T MR scanner. The mice were anesthetized using isoflurane inhalation anesthesia and contrast was injected via the tail vein. In order to validate the MR imaging method of in vivo tumor detection in this mouse model, we scanned and subsequently sacrificed UPII-Ha-ras-M mice at 3, 4, 6, 8 ...
A series of transitional cell carcinomas and mucosal biopsy specimens of bladder were stained immunohistochemically with the monoclonal antibody HMFG-2. Staining characteristics ranged from luminal staining in well differentiated, superficial lesions to staining of all cells in invasive carcinomas. Invasive tumour nests also stained strongly with the antibody. There was good correlation between the staining pattern and histological assessment of both tumours and mucosal biopsy specimens. Correlation with clinical course showed that it was also a good predictor of subsequent disease progression of superficial tumours. It is suggested that HMFG-2 staining is a sensitive indictor of malignant transformation and that it may have a role as an adjunct to conventional histological examination in the assessment of urothelial carcinomas.. ...
The pathophysiology of IC is complex and not completely understood. This makes it difficult to develop definitive therapeutic modalities and to establish a standard animal model for translational research. Current approaches have mostly emphasized merging clinical practice and translational research; therefore, it is important to establish proper translational models similar to the disease in humans. Approximately 20 animal models with some similar characteristics to the IC phenotype have been generated over the past several decades [15,18]. From 1980 to 2000, the models were typically prepared by inducing inflammatory conditions in the bladder by intravesical instillation of chemical irritants, such as acetone, acrolein, acid, turpentine, mustard oil, or croton oil [19-22]. In the 2000s, IC animal models were commonly generated by injection of bacterial LPS, systemic administration of CYP, pseudorabies virus infection, or systemic induction of autoimmunity [9,14,16,23,24]. Although these ...
Evaluation of the intravesical ureters after failed endoscopic treatment of vesicoureteral reflux with dextranomer/hyaluronic acid in children via light and transmission electron microscopic analysis. A Matched Case-Control Study. Urol J. 2018 Aug 26;: Authors: Izol V, Kuyucu Y, Acikalin A, Deger M, Aridogan IA, Polat S, Satar N Abstract INTRODUCTION: The cytokine profile and...
PhD Project - Changes in selective biomarkers after transurethral resection of a bladder tumour (TURBT) and their association with Non-muscle invasive bladder cancer (NMIBC) recurrence and progression, as well as post-operative complications. at University of Chester, listed on FindAPhD.com
A previous study by our group demonstrated that the expression levels of Notch 1 and Jagged 1 in bladder cancer cells was significantly lower compared with those in normal bladder mucosa, while the expression levels of Notch 1 and Jagged 1 in invasive bladder cancer were higher compared with those in superficial bladder cancer. The present study investigated the effect of the Notch signaling pathway on the drug resistance and invasiveness of bladder cancer cells. It was demonstrated that complete inhibition of the Notch signaling pathway induced significant morphological changes and inhibited cell proliferation and migration ( ...
A prospective observational study to evaluate the role of restaging transurethral resection of bladder tumour in patients with non-muscle invasive bladder cancer
Invasive bladder cancer , Invasive bladder cancer , کتابخانه دیجیتالی دانشگاه علوم پزشکی و خدمات درمانی شهید بهشتی
BACKGROUND: Treatment with Bacillus Calmette-Guérin (BCG) is the gold standard adjuvant immunotherapy of non-muscle invasive bladder cancer (NMIBC), although it fails in one third of the patients. NMIBC expresses two tumor-associated O-linked carbohydrates: the disaccharide (Galβ1,3GalNAc) Thomsen-Friedenreich (T) antigen, and its sialylated counterpart (Siaα2,3Galβ1,3GalNAc) sialyl-T (sT), synthesized by sialyltransferase ST3GAL1, whose roles in BCG response are unknown. METHODS: The human bladder cancer (BC) cell line HT1376 strongly expressing the T antigen, was retrovirally transduced with the ST3GAL1 cDNA or with an empty vector, yielding the cell lines HT1376sT and HT1376T , that express, respectively, either the sT or the T antigens ...
Thirty cows from a pedigree Friesian dairy herd with bovine vulva papilloma and carcinoma were treated by intralesional injections of live bacillus Calmette-Guérin (BCG). This treatment induced total regression of all of six carcinomas. Whilst, after treatment, limited regression was also observed in advanced papillomas, BCG has little or no effect on the early stages of papillomas. This is the first study of BCG therapy in this type of cancer.
The majority of agents used in the treatment of IC/PBS are not approved by the Food and Drug Administration (FDA) for this indication. Oral pentosan polysulfate sodium (PPS) and intravesical dimethylsulfoxide (DMSO) are the only FDA-approved agents. The majority of medications mentioned in this Quick Reference Guide have either shown efficacy in non-FDA-based clinical trials or are used in clinical practice by advisory committee members. ...
... Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Pipeline Review, H2 2017, provides an overview of the Bladder Cancer
Read about bladder cancer symptoms, signs, treatment, prognosis, survival rates, staging, and causes. Find out how bladder tumors are diagnosed and about the different types of bladder cancer.
... : Patients Guide - Causes and symptoms of bladder cancer - Please contact a doctor if any of these symptoms occur
Get help for treatment of your bladder cancer. Learn about the symptoms of this disease and your treatment options for the different stages of cancer.
Learn more about In his own words: living with bladder cancer at Grand Strand Medical Center Norman is 70 years old and lives in Spooner, Wisconsin, where he owns...
Learn more about In his own words: living with bladder cancer at Grand Strand Medical Center Norman is 70 years old and lives in Spooner, Wisconsin, where he owns...
BCG Failure BCG χρησιμοποιείται σαν συμπληρωματική θεραπεία σε Intermediate και κυρίως High Risk NMIBC (high grade, T1, CIS) Περίπου 40-50% των ασθενών θα υποτροπιάσουν /εξελιχθούν Αυτό ορίζεται γενικά ως «αποτυχία του BCG» -BCG failure
BLADDER CANCER TREATMENT AND METHODS - Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better adhesion of the coating composition to the bladder wall during intravesical delivery of the coating composition ...
In this study, we compared the effects of the Src inhibitor dasatinib on the urothelial cancer cell line RT112 and its gemcitabine-resistant sub-line RT112rGEMCI20 in cell culture and in an orthotopic bladder cancer xenograft model in mice.. In cell culture, both cell lines displayed similar growth kinetics. Dasatinib inhibited Src phosphorylation in RT112 and RT112rGEMCI20 cells at low nanomolar concentrations similar to those that had already been described to affect Src phosphorylation [9]. While dasatinib had previously been shown to interfere with the phosphorylation of Akt (Thr308 and Ser473) in squamous cell lung cancer [22], we only detected inhibition of phosphorylation of Akt (Thr308). The reasons for this may be the consequence of cell type-specific differences between the investigated models. Although dasatinib exerted similar effects on Src signaling in RT112 and RT112rGEMCI20 cells, its effects on cell viability differed between the two cell lines. The effective concentrations of ...
A bladder cancer drug tested in a University of Hawaiʻi Cancer Center clinical trial gets closer to Food and Drug Administration approval. The new drug, an interleukin 15 superagonist complex (ALT-803), combined with Bacillus Calmette-Guerin (BCG) is expected to be more effective for patients with non-muscle invasive bladder cancer, the most common type of bladder cancer, as reported by UH.. "The last time the FDA approved a drug for bladder cancer was almost two decades ago. Bladder cancer treatment hasnt advanced very much, BCG has been the main drug used to treat the disease since the 80s," said Dr. Charles Rosser, director of the UH Cancer Centers Clinical Trials Office. "The science field has changed so much since then. We may finally be able to move the field forward and get better drugs to patients.". Phase II of the study was recently Institutional Review Board and FDA approved. The first patient for Phase II was enrolled on Oct. 15. The Phase II study will have about 124 ...
Inclusion Criteria:-Histologically confirmed, locally confined adenocarcinoma of the prostate -Clinical stages T1a to T2c PSA of less than 20 ng per ml -Gleason score of less than 8 -The patient has decided to undergo external beam radiation as treatment choice for his prostate cancer -Signed study-specific consent form prior to registrationExclusion Criteria:-Stage T3 to 4 disease -Gleason 8 or higher score -PSA greater than 20 ng per ml -Clinical or Pathological Lymph node involvement N1 -Evidence of distant metastases M1 -Radical surgery for carcinoma of the prostate -Previous Chemotherapy or pelvic radiation therapy -Previous or concurrent cancers other than basal or squamous cell skin cancers or superficial bladder cancer unless disease free for at least 5 years -History of inflammatory bowel disease -Major medical or psychiatric illness which, in the investigators opinion, would prevent completion of treatment and would interfere with follow up ...
Stanford University School of Medicine researchers have discovered a single type of cell in the lining of the bladder that is responsible for most cases of invasive bladder cancer.
Bladder cancer patients may have a biologic treatment called Bacillus Calmette-Guérin (BCG) to help prevent the cancer from recurring.
Bladder Cancer What is bladder cancer? Bladder cancer occurs when there are abnormal, cancerous cells growing in the bladder. According to the American Cancer Society (ACS), 70,980 cases of bladder cancer will be diagnosed in the US in 2009. Bladder cancer affects men about three times more often than women, and it occurs in Caucasians twice as often as in African Americans. The risk of bladder cancer increases with age - over 70 percent of people who are diagnosed with it are older than 65. Click Image...
Superficial bladder tumors are those that are localized (confined) to the transitional epithelium (urothelium) - the layer of epithelial cells that lines the inside of the bladder wall and is in direct contact with the urine - but have not spread to the deeper layers of the bladder. Additionally, bladder tumors that have invaded the lamina propria but have not invaded the muscularis propria can be considered as superficial. Invasive bladder cancer refers to a bladder tumor that is either invading the muscularis propria - the deeper layer of muscle cells that forms the wall of the bladder - or the perivesical fat located beyond the bladder muscle. This type of tumor is referred to as muscle-invasive bladder cancer. Muscle-invasive bladder cancer carries a higher risk of spreading beyond the bladder (metastases) and must be treated more aggressively than superficial bladder cancer. The term metastatic bladder cancer is used when the cancer cells have spread beyond the bladder to distant ...
Aims The C-fiber-mediated bladder-cooling reflex and the determination of the current perception thresholds (CPTs) permit to investigate afferent LUT pathways. They have both been proposed to detect and differentiate neurologic bladder dysfunction. This study evaluates, prospectively, the effect of oxybutynin, an antimuscarinic with direct antispasmodic effect on smooth muscle, on repeated ice water test (IWT) and CPTs in patients with a known incomplete neurogenic bladder. Methods Patients with a known incomplete lesion of the bladder innervation, detrusor overactivity during cystometric bladder filling and a continuous positive response to repeated IWT were included. After the initial tests, 30 mg intravesical oxybutynin (1 mg/ml) was instilled and left in the bladder for 15 min. Afterwards CPTs and IWT were re-assessed. Results After the drug application, the bladder-cooling reflex could not be initiated, even after three instillations, in 16/17 patients. The bladder CPT increased from 29.7 ...
Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!. New report on global Urinary Tract Cancer market is segmented on the basis of types, diagnostic techniques, treatment procedures and geography. On the basis of types urinary tract cancer market is further categorized into Urothelial carcinoma, Squamous cell carcinoma, Adenocarcinoma and others. Among the urinary tract cancer types, urothelial carcinoma is the most-prevalent with ~90% to 95% occurrence rate, globally. Based on diagnostic techniques it is segmented into Cystoscopy, Urine analyses, Transurethral resection of tumor and Imaging tests. Being a part of initial evaluation in diagnosis of any urinary tract cancer, cytoscopy is the most important investigation for bladder cancer. Segmentation on the basis of treatment procedures categorizes the market into Surgery, Intravesical therapy, Chemotherapy, and Radiation therapy. Geographically, the global urinary tract cancer market is segmented into North ...
Transurethral Resection of Bladder Cancer (TURBT): Find the most comprehensive real-world treatment information on Transurethral Resection of Bladder Cancer (TURBT) at PatientsLikeMe. 2 patients with fibromyalgia, multiple sclerosis, major depressive disorder, generalized anxiety disorder, systemic lupus erythematosus, diabetes type 2, post-traumatic stress disorder, rheumatoid arthritis, bipolar disorder, Parkinsons disease, panic disorder, high blood pressure (hypertension), myalgic encephalomyelitis/chronic fatigue syndrome, amyotrophic lateral sclerosis, persistent depressive disorder (dysthymia), epilepsy, migraine, hypothyroidism, osteoarthritis, attention deficit/hyperactivity disorder, bipolar II disorder, traumatic brain injury, asthma, social anxiety disorder, high cholesterol (hypercholesterolemia), irritable bowel syndrome, idiopathic pulmonary fibrosis, gastroesophageal reflux disease, bipolar I disorder or mild depression currently have Transurethral Resection of Bladder Cancer (TURBT).
Interstitial Cystitis (IC) Treatment -  Interstitial Cystitis - HealthCommunities.com  Interstitial Cystitis (IC) Treatment - Interstitial Cystitis - HealthCommunities.com
Pentosan polysulfate sodium (Elmiron) is the only oral medication approved by the Food and Drug Administration (FDA) for IC. It ... Dimethyl Sulfoxide (DMSO, Rimso-50) may be instilled (intravesical) through the urethra and directly into the bladder via a ...
more infohttp://www.healthcommunities.com/interstitial-cystitis/treatment-medical.shtml
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer - Full Text View -...  Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer - Full Text View -...
Subjects who cannot tolerate intravesical dosing or intravesical surgical manipulation. *Intravesical therapy within 6 weeks of ... Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer. The safety and ... The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be ... The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be ...
more infohttps://clinicaltrials.gov/ct2/show/NCT01687244
1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory...  1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory...
1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory ... 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory ... Phase 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG ... Subjects who have a complete response to treatment at Week 12 in Part 1 receive second regimen of intravesical administration ...
more infohttps://clinicaltrials.gov/ct2/show/record/NCT01162785
Contrast-enhanced voiding urosonography with intravesical administration of a second-generation ultrasound contrast agent for...  Contrast-enhanced voiding urosonography with intravesical administration of a second-generation ultrasound contrast agent for...
To evaluate the safety of intravesical administration of a second-generation ultrasound (US) contrast agent for the diagnosis ... Thus, ce-VUS with intravesical administration of the second-generation US contrast agent (SonoVue®) for vesicoureteral reflux ... Contrast-enhanced voiding urosonography with intravesical administration of a second-generation ultrasound contrast agent for ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed/?term=24442338
Pancreatic and psoas abscesses as a late complication of intravesical administration of bacillus Calmette-Guerin for bladder...  Pancreatic and psoas abscesses as a late complication of intravesical administration of bacillus Calmette-Guerin for bladder...
This case illustrates the fact that although intravesical administration of bacillus Calmette-Guerin is generally considered to ... diagnosed 5 years after intravesical treatment with bacillus Calmette-Guerin therapy for bladder cancer. An 83-year-old ... two transurethral resections for high-grade transitional cell carcinoma of the bladder and had received 12 intravesical ... Intravesical administration of BCG has proved to be an effective form of treatment for some stages of bladder cancer [4]. There ...
more infohttps://jmedicalcasereports.biomedcentral.com/articles/10.4076/1752-1947-3-7323
Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent...  Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent...
Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent ... Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent ... Objectives: To compare the clinical effectiveness of the intravesical administration of combined hyaluronic acid and ... Interventions: Patients treated with either intravesical administration of HA+CS or standard of care (antimicrobial/ ...
more infohttps://iris.unibocconi.it/handle/11565/3989572
Toxicology and Pharmacokinetics of Intravesical Gemcitabine: A Preclinical Study in Dogs | Clinical Cancer Research  Toxicology and Pharmacokinetics of Intravesical Gemcitabine: A Preclinical Study in Dogs | Clinical Cancer Research
At all intravesical doses, significant systemic absorption was seen. The T1/2 (±SD) for intravesical and i.v. administration of ... We have demonstrated a markedly prolonged half-life after intravesical administration when compared with i.v. administration. ... Intravesical Administration.. Animals (n = 6) were initially treated with 350 mg (n = 1) and 3.5 g (n = 1) of drug, and blood ... Serum gemcitabine levels after 350 mg (n = 2) of drug by i.v. (♦; X) administration and by intravesical (. , , ▪) ...
more infohttp://clincancerres.aacrjournals.org/content/5/9/2629.long
Advanced Practice | Society of Urologic Nurses and Associates  Advanced Practice | Society of Urologic Nurses and Associates
Joint Statement on Intravesical Administration of Therapeutic Medication SUNA and the American Urological Association (AUA) ... Read more about Joint Statement on Intravesical Administration of Therapeutic Medication. Consensus Statement on Advanced ... developed a joint Statement of Practice on Intravesical Administration of Therapeutic Medication. The purpose of the statement ... is to define the performance guidelines surrounding the instillation of intravesical cytotoxic, immunotherapeutic, and/or ...
more infohttps://www.suna.org/resource/advanced-practice
Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis  Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis
Administration, Intravesical. The instillation or other administration of drugs into the bladder, usually to treat local ... A single intravesical instillation of Lactobacillus rhamnosus GG is safe in children and adults with neuropathic bladder: A ... A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer ... Surgical intervention combined with intravesical instillation of chemotherapeutics to clear residual cancer cells after ...
more infohttps://www.bioportfolio.com/resources/trial/242275/Treatment-of-High-risk-Non-muscle-Invasive-Bladder-Cancer-With-IMUNO-BGC.html
Epididymo-orchitis following intravesical bacillus Calmette-Guérin therapy.  Epididymo-orchitis following intravesical bacillus Calmette-Guérin therapy.
To describe a case of epididymo-orchitis that developed four years after treatment with intravesical bacillus Calmette-Guérin ( ... Administration, Intravesical. Aged. BCG Vaccine / adverse effects*, therapeutic use. Carcinoma, Transitional Cell / ... OBJECTIVE: To describe a case of epididymo-orchitis that developed four years after treatment with intravesical bacillus ...
more infohttp://www.biomedsearch.com/nih/Epididymo-orchitis-following-intravesical-bacillus/10772435.html
American Urological Association - Guidelines  American Urological Association - Guidelines
Intravesical Administration of Therapeutic Medication Policy Statements. JCAHO Universal Protocol for Preventing Wrong Site, ...
more infohttps://www.auanet.org/guidelines?q=&ContentType=Policy_Statements%7C&filters=
Guidelines - American Urological Association  Guidelines - American Urological Association
Intravesical Administration of Therapeutic Medication Policy Statements. JCAHO Universal Protocol for Preventing Wrong Site, ...
more infohttps://www.auanet.org/guidelines?q=&
American Urological Association - Guidelines  American Urological Association - Guidelines
Intravesical Administration of Therapeutic Medication Policy Statements. JCAHO Universal Protocol for Preventing Wrong Site, ...
more infohttp://auanet.org/guidelines
terodiline
      - TD 758
     Summary Report | CureHunter  terodiline - TD 758 Summary Report | CureHunter
12/01/1992 - "Intravesical administration of terodiline may offer an alternative treatment in selected patients with detrusor ...
more infohttp://www.curehunter.com/public/keywordSummaryC010637-terodiline-TD-758.do
keyhole-limpet hemocyanin
      - keyhole limpet hemocyanin
     Summary Report | CureHunter  keyhole-limpet hemocyanin - keyhole limpet hemocyanin Summary Report | CureHunter
06/01/2006 - "Administration of autologous tumor-derived idiotype protein conjugated to a carrier protein, keyhole limpet ... were determined in the MB-49 intravesical murine bladder tumor model. ". 03/01/1993 - "Keyhole limpet hemocyanin (KLH) is a ...
more infohttp://www.curehunter.com/public/keywordSummaryC032808-keyhole-limpet-hemocyanin-keyhole-limpet-hemocyanin.do
Theracys Advanced Patient Information - Drugs.com  Theracys Advanced Patient Information - Drugs.com
Serious and fatal disseminated BCG infections have occurred with intravesical administration . Manifestations of disseminated ... Theracys (Intravesical). Generic Name: bacillus of calmette and guerin vaccine, live (Intravesical route) ... Intravesical route(Powder for Suspension;Powder for Solution) Bacillus of Calmette and Guérin (BCG) infections have been ... reported in health care workers and in patients because of exposure to the vaccine during preparation and administration. ...
more infohttps://www.drugs.com/cons/theracys.html
Cardoso JC[au] - PubMed - NCBI  Cardoso JC[au] - PubMed - NCBI
Decreased inflammatory response in rat bladder after intravesical administration of capsaicin-loaded liposomes. ...
more infohttps://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Cardoso+JC%5Bau%5D&dispmax=50
UROCIDIN™ PHASE III CLINICAL TRIAL RESULTS PRESENTED AT AUA CONFERENCE IN WASHINGTON, D.C.  UROCIDIN™ PHASE III CLINICAL TRIAL RESULTS PRESENTED AT AUA CONFERENCE IN WASHINGTON, D.C.
The preliminary results indicate that intravesical administration of Urocidin™ was well tolerated. ... UrocidinTM is an intravesical infusion therapy, administered via trans-urethral catheter into the bladder. ... This form of bladder cancer is treated predominantly by urologists using surgical resection and intravesical infusion therapy. ... being developed for the intravesical treatment of non-muscle invasive bladder cancer. Under the licensing agreement, Bioniche ...
more infohttps://www.newswire.ca/news-releases/urocidin-phase-iii-clinical-trial-results-presented-at-aua-conference-in-washington-dc-508246671.html
Medline ®
		
			
			
				Abstract for Reference
			
		
		129 of Infusion reactions to systemic chemotherapy  Medline ® Abstract for Reference 129 of 'Infusion reactions to systemic chemotherapy'
Adverse reactions to the intravesical administration of doxorubicin hydrochloride: report of 6 cases. ... We report 6 cases of adverse systemic reactions to the intravesical instillation of doxorubicin hydrochloride for the treatment ...
more infohttp://www.uptodate.com/contents/infusion-reactions-to-systemic-chemotherapy/abstract/129
  • Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit. (bioportfolio.com)